The Latest Breaking News from AbbVie

A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue?

AbbVie stock won at least one upgrade Friday after issuing long-awaited guidance for Humira for the first year it faces new competition.

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.

NHS crisis, withdrawal of tax credits and exit from EU blamed for fall in UK share of R&D market

While the stock market and the economy have been subdued by progressive interest-rate increases, AbbVie Inc. (ABBV) has not only reported a robust third quarter but also demonstrated its confidence in its long-term prospects by raising its quarterly dividend. Read on….

AbbVie stock briefly broke out Friday after the company signed a $30 million deal with small biotech Immunome in antibody development.

Legendary investor Warren Buffett’s holding company Berkshire Hathaway has outperformed the broader market over the past year. His investment portfolio has been a guide for several long-term investors for decades. Amid a highly uncertain market and economic backdrop, Warren Buffett holdings Procter & Gamble (PG), AbbVie (ABBV), Biogen (BIIB), and…

The Dow Jones plunged as recession fears rose. Tesla stock suffered a shocking fall. Some Cathie Wood buys got battered. Apple stock dived.